SAM Curran took five wickets before England captain Eoin Morgan and Joe Root both hit unbeaten fifties as the 50-over world champions cruised to a series-clinching win over Sri Lanka in the second one-day international at the Oval in London on Thursday (1).
England finished on 244-2 with seven overs to spare for an eight-wicket victory that put them 2-0 up in a three-match campaign ahead of Sunday's (4) finale in Bristol.
Morgan was 75 not out -- only his second fifty in 17 international innings -- whereas Test skipper Root's unbeaten 68 followed his 79 not out during England’s five-wicket win in the series opener at Chester-le-Street.
The third-wicket pair shared an unbroken stand of 140.
Player-of-the-match Curran, starring on his Surrey home ground, set up the victory with his ODI best 5-48 - his first five-wicket haul in international cricket.
Fellow left-arm paceman David Willey (4-64) was the only other bowler to take wickets in Sri Lanka's 241-9.
"It was really special to get my first five-for and to be playing in front of fans as well," Curran, 23, appearing in just his 10th ODI, told Sky Sports.
"I feel like I have played a lot of cricket but I'm learning from every game I play and learning from other players."
Morgan added: "It was a good day all-round. As a captain, I don't think massively about my batting. Today it was nice to get some time in the middle and hopefully, the runs continue."
It looked like a Covid-reduced crowd of 14,000 for the day/night match would leave before the floodlights were switched on in south London when Sri Lanka slumped to 21-4 inside seven overs after losing the toss.
But Dhananjaya de Silva's run-a-ball 91 kept them in the match and he received good support from Dasun Shanaka (47) in a sixth-wicket stand of 78.
"When we fell to 21-4, that is very hard to get back in the game but it was good to see Dhananjaya de Silva and Dasun Shanaka get us back on track," said Sri Lanka captain Kusal Perera.
Jonny Bairstow and Jason Roy ensured England made a brisk start to their chase before the former chopped-on to leg-spinner Wanindu Hasaranga for 29.
Roy, like Curran playing on his home ground, pressed on to 60 before he was well caught by a diving de Silva at midwicket off Chamika Karunaratne.
England, however, remained in command, with Morgan making a run-a-ball fifty.
Batting had been a problem for a Sri Lanka side missing vice-captain Kusal Mendis, opener Danushka Gunathilaka and wicketkeeper Niroshan Dickwella, who were all sent home for breaching Covid regulations.
Curran, recalled in place of the rested Chris Woakes, struck with his second ball when Perera was lbw for a duck after top-scoring for Sri Lanka with 73 on Tuesday (29).
Two balls later, still in the second over, Avishka Fernando was also lbw to Curran.
Sri Lanka slumped to 12-3 when Pathum Nissanka was clean bowled between bat and pad by Curran on the drive.
The collapse continued with Charith Asalanka mistiming a pull off Willey to short mid-wicket.
At 21-4, Sri Lanka were in danger of being dismissed for less than their record low ODI total of 43 all out against South Africa in Paarl in 2012.
But de Silva, stroking some stylish boundaries off an England attack that included Tom Curran, Sam's brother, meant they avoided the embarrassment.
De Silva fell nine short of a maiden ODI hundred as he too perished to the short ball, top-edging a pull off Willey to Root before Sri Lanka managed to bat out their overs.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.